All In Biotech

Drug Trial Radar · NCT01869491

Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study

A Multi-centre, Randomised, Double-blind, Two Arm, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Double Action Chewable Tablets in Patients With Gastro-esophageal Reflux Disease

Last checked: Nov 20, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,107 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,107

Actual

Start

Jun 5, 2013

Primary completion

May 2014

Study completion May 2014

Sponsor

Sponsor type
Industry
First posted
Jun 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to provide evidence that Compound Sodium Alginate Double Action Chewable Tablets are effective in managing the symptoms of heartburn, acid regurgitation and dyspepsia in patients with Gastroesophageal Reflux Disease (GERD).

Conditions

  • Gastroesophageal Reflux Disease
  • Dyspepsia

Interventions

  • Compound Sodium Alginate Double Action Chewable TabletsDrug

    2 tablets four times daily

  • Matching placebo tabletsDrug

    2 tablets four times daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Reflux Disease Questionnaire (RDQ) Scores for the GERD DimensionTime frame: 7 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • RB Investigational Sites

    Beijing, China

  • RB Investigational Sites

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.